Google
AKTX — AKARI THERAPEUTICS PLC (Healthcare >> Biotechnology)
AKTX FAQ
What is AKTX's ROE?
AKARI THERAPEUTICS PLC reports a Return on Equity (ROE) of -195.05%.
What is AKTX's dividend yield?
AKARI THERAPEUTICS PLC offers a dividend yield of 0.00%.
What is AKTX's Deepscope Quality Score?
Deepscope rates AKTX's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AKTX?
Deepscope's AI Timing Score for AKTX is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AKTX belong to?
AKARI THERAPEUTICS PLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 15.84
Price
0.86
(5.71%)
Day Change
|
|
|---|
AKTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 56 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 15.84 |
| PBV / Sector |
1.22 / 4.58
GOOD
|
| Earning Per Share | -25.37 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
34.47 M
GREAT
|
| Average 1W Daily Value |
3.44 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-05 09:12:38 |
| Symbol | AKTX |
| Name | AKARI THERAPEUTICS PLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 1.14 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 17.51 / 8,655.90 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 401 East Jackson Street, Tampa, FL, United States, 33602
Phone: 929 274 7510
Website: https://www.akaritx.com
Sector: Healthcare >> Biotechnology
Description: Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
